HuMeds has signed a business agreement with Baro Pharm to distribute its functional cosmetic brand 'Elavie Re2O ECM' through pharmacy channels in South Korea, aiming to boost accessibility and competitiveness in the derma-cosmetic market. The partnership combines HuMeds' manufacturing expertise with Baro Pharm's pharmacy distribution platform, targeting both domestic and international consumers.
Partnership details
HuMeds CEO Kang Min-jong and Baro Pharm CEO Kim Seul-gi signed the agreement on April 8 at HuMeds' headquarters in Seongnam-si, Pangyo. The collaboration focuses on expanding the nationwide pharmacy presence of the Re2O ECM line through joint marketing and a shared distribution network.
Product highlights
The Re2O ECM line features HuMeds' proprietary 'ECMiracle' ingredient at 10,000 ppm, designed to support skin elasticity. Clinical trials have confirmed improvements in skin barrier integrity, density, nasolabial fold reduction, and skin texture. The line includes an active ampoule, booster cream, and skin-fit BB cream, and is positioned for post-procedure care, particularly after Re2O treatments.
Market and channel signals
HuMeds expects the pharmacy channel to capture meaningful domestic market share, given the product's clinical validation. The company also notes growing demand from foreign tourists for pharmacy-exclusive cosmetics focused on post-treatment care and skin firming, which could amplify global brand exposure.
Sourcing context
For overseas buyers and distributors, this partnership signals HuMeds' strategy to leverage regulated pharmacy channels for premium derma-cosmetic distribution. The Re2O ECM line has already been showcased at international trade fairs, indicating potential for export expansion. The official launch on Baro Pharm's platform is scheduled for April 22, with promotional activities planned.
Source: Read the original report | Published: June 09, 2026